How to Characterize Stem Cells using Immunocytochemistry

    Planning an immunocytochemistry (ICC) project can be tricky as it requires careful selection of compatible antibodies, fluorochromes, and blocking reagents. In this article our scientists have provided a step-by-step guide for single staining of iPSCs, plus trouble-shooting tips you can use to optimize your results. 

    Continue reading 

    5 factors to consider when planning a stem cell reprogramming project

    When you are planning a project involving stem cell reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider. This post will highlight 5 questions you may want to answer before choosing a service provider or reprogramming technology.

    Continue reading 

    Pluripotent Potential for Clinical Application

    Since their development in the mid-2000s, the versatile nature of induced Pluripotent Stem Cells (iPSCs) has unlocked the potential of curative approaches instead of symptom-reactive treatments. In particular, fields which deal with genetic disorders and regenerative therapies would benefit from this. The advancement of iPSC technology compliments the advent of personalized medicine, allowing for a future where individuals could be treated using autologous iPSCs.

    Continue reading 

    Tissue Sourcing for the Development of iPSC-derived Disease Models

    Human induced pluripotent stem cells (iPSCs)-based models are an ideal resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by drug treatment[3]. Such iPSC-based models enable studies to be performed under defined experimental conditions and in a reproducible manner.

    Continue reading 

    Five reasons to choose StemRNA 3rd Gen reprogramming

    RNA Reprogramming is used globally for the generation of integration-free induced pluripotent stem cells (iPSCs) by researchers in biotech, academia, research hospitals and government agencies. This reprogramming method is gaining more and more interest and core labs and biotech companies focusing on regenerative medicine and GMP compatibility are adopting this technology and make it their standard.

    Continue reading